
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics Inc. is advancing its clinical pipeline with cadisegliatin, an oral liver-selective glucokinase activator currently in Phase 3 trials for type 1 diabetes, enhancing its market potential. The company's updated projections reflect improved market penetration rates, increasing the risk-adjusted discounted cash flow (DCF) valuation and reflecting greater long-term conviction in the therapeutic's prospects. With continued positive developments in ongoing studies and a strategic positioning in a market with limited competition for oral therapies, vTv Therapeutics's outlook appears promising.
Bears say
vTv Therapeutics's stock outlook appears negative primarily due to the inherent clinical risks associated with its lead product, cadisegliatin, which is still in late-stage development and may face challenges such as slower patient enrollment and unanticipated safety or efficacy results that could fail to meet expectations. The historical issues with first-generation glucokinase activators, which resulted in complications such as excessive hypoglycemia and worsening lipid profiles, highlight significant concerns regarding the efficacy and safety of vTv's therapeutic approach. Furthermore, the troubling statistic that nearly 80% of adults with type 1 diabetes do not achieve the American Diabetes Association's A1C goal of <7% underscores the potential limitations in addressing chronic disease management effectively, complicating vTv's prospects for successful market penetration.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares